






EUS in Ca pancreas Diagnosis: FNA, Trucut Staging of CA pancreas Treatment: Locally invasive / borderline resectable tumor: Fiducial placement Unresectable tumor: CPN, biliary drainage, delivery of anti-tumoral agents







































Lymph node staging EUS vs CT			
	EUS	СТ	
Sensitivity	75%	38%	
Specificity	97%	100%	
Positive predictive value	75%	100%	
Negative predictive value	98%	95%	
		a negroup of Medicines Faculty of Medicines The Coresi Chromoty of Hong Acod	






Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis

- 19 studies
- 1019 patients
- Squamous and adenocarcinomas
- Pooled analysis:
- T1a: Sensitivity 0.85 (95% CI, 0.82-0.88), Specificity 0.87 (95% CI, 0.84-0.90)
- T1b: Sensitivity 0.86 (95% CI, 0.82-0.89), Specificity 0.86 (95% CI, 0.83-0.89)

Thosani GIE 2012



カー文人参加参照 aculty of Medici




Selective use of EUS for EEC Squamous esophageal carcinoma If high certainty for mucosa involvement only => EMR/ESD If suspicious of SM involvement => EUS Adenocarcinoma esophagus If high certainty of mucosal or SM involvement only => EMR/ESD EUS performed to rule out T2 involvement

Advanced Esophageal cancers Role of EUS Determine patients for neoadjuvant or definitive CRT ■ N +ve


- Serosal involvement
- Assess presence of adjacent organ invasion
 Trachea


 - Aorta
 - Pleura







Accuracy of EUS in advanced esophageal cancers			
Technique	No. of studies patients	T accuracy % (range)	N accuracy % (range)
СТ	1154	45 (40-50)	54 (48-71)
EUS	1035	85 (59-92)	77 (50-90)
	Rosch GI endosc Clin N Am 1995		
Technique	No. of studies	Sensitivity (%)	Specificity (%)
CT T stage	5	40-80	14-97
EUS T stage	13	71-100	67-100
CT N stage		40-73	25-67
EUS N stage 20	20	60-97	40-100








AJCC 7 th edition	TX	Primary tumor cannot be assessed	
AJCC / Edition	TO	No evidence of primary tumor	
Ca Stomach	Tis	Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria	
	TI	Tumor invades lamina propria, muscularis mucosae, or submucosa	
	Tla	Tumor invades lamina propria or muscularis mucosae	
 Changes in 	TIb	Tumor invades submucosa	
definition _	T2	Tumor invades muscularis propria	
• T3 & T4	T3	Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures. T3 tumors also include those extending into the gastrocolic or gastrobepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures	
	T4	Tumor invades serosa (visceral peritoneum) or adjacent structures	
	T4a	Tumor invades serosa (visceral peritoneum)	
 Nodal 	T4b	Tumor invades adjacent structures such as spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum	
Γ	NX	Regional lymph node(s) cannot be assessed	
	N0	No regional lymph node metastasis	
	NI	Metastasis in 1 to 2 regional lymph nodes	
	N2	Metastasis in 3 to 6 regional lymph nodes	
	N3	Metastasis in 7 or more regional lymph nodes	


























Accuracy of EUS Advanced gastric cancers						
Auvanceu gastine cancers						
T staging	Patients	EUS (%)	CT (%)	MRI (%)		
Ziegler et al	108	86	43	-		
Kuntz and Herfath	82	73	51	48		
Bhandari	63	88	83	-		
N staging	Patinets	EUS (%)	CT (%)	MRI (%)		
Kuntz and Herfath	82	87	65	69		
Zielga	108	74	51	-		
Bhandari	48	79	75	-		





















Procedure	Advantages	Disadvantages
Thoracotomy (surgical opening of the chest)	Allows the most thorough inspection and sampling of lymph node stations, may be followed by resection of tumor, if feasible	Most invasive approach, not indicated for staging alone, significant risk of procedure-related morbidity
Left parasternal mediastinotomy	Access to station 5 (aortopulmonary window lymph node)	Limited applications, invasive
Cervical mediastinoscopy	Still considered the gold standard by many, excellent for 2RL 4RL	Does not cover all medastinal lymph node stations, invasive
Video-assisted thoracoscopy	Good for inferior mediastinum, station 5 and 6 lymph nodes	Invasive, does not cover superior anterio mediastinum
Transthoracic percutaneous FNA under CT guidance	More widely available than some other methods	Traverses a lot of lung tissue, therefore high pneumothorax risk, some lymph node stations inaccessible
Bronchoscopy with plind transbronchial FNA	Less invasive than above methods	Relatively low yield, not widely practiced bleeding risk
Endobronchial ultrasound (EBUS)	Direct visualization of lymph node stations. Complements EUS: covers lymph node stations 2R and 4R which are difficult to access by EUS	More invasive than EUS, few practitioners, but rapidly growing in popularity
Endoscopic ultrasound (EUS)	Least invasive modality, uses the esophagus to access mediastinal lymph nodes, excellent for station 5, 7, 8 lymph nodes. Useful for station 2L and 4L, L adrenal, celiac lymph node and liver	Cannot reliably access right sided paratracheal lymph node stations 2R and 4R






























































Nagi stent for pseudocyst

- 9 patients (5 pseudocyst and 4 WOPN)
- 100% technical success rates
- 77.8% clinical success
- No early complications
- 2 late complications (bleeding and migration)
- 100% removal





Potential advantages潜在的好处

- 1. Logistic advantage逻辑优势
 - Performed in the same session as ERCP
 - 在ERCP检查同一进行
- 2. Physiological advantage生理优势
 - Internal drainage without need of external drains 体内引流术无需体外引流
- 3. Anatomic advantages引流管道优势
 - Options of anatomical drainage available according to patient可根据患者的选择引流位置




東中文大學無単名 Faculty of Medic


Indications引流**原因**

Any cause of failure to access the bile duct 任何插管失败原因

- Failed ERCP ERCP失败
- Malignant obstruction of duodenum十二指肠恶性梗阻
- Surgically altered anatomy 手术改道













EUS Bile duct drainage 超声内镜引导下胆管引流术 • Technical success rates成功率 80-100% • Complication rates并发症率 • 11 - 20% • Most common pneumoperitoneum气腹 • Bile leak胆漏 • Bleeding出血 • ? Dependent on access and drainage routes • 取决于穿刺和引流途径


The important question!! Does EUS methods provide longer patency as compared to ERCP and SEMS? 超声内镜方法和ERCP相比, 支架通畅率谁比较好? Is EUS BD comparable to surgery in terms of patency? 是超声内镜胆管引流相比手术引流,通畅率谁比较好?

















EGBD vs PTC [1]					
	EGBD N = 58	PTC N = 58	P-value		
Age (years)	83.83 (7.32)	81.22 (7.94)	0.312		
ASA grade I/II/III/IV	1/4/9/4	1/5/8/4	0.982		
EGBD may potentially replace PC as the treatment of choice in patients that are unfit for surgery					
Mortalities (%)	2 (11.1)	1 (5.6%)	1		
Unplanned admissions (%)	6.9	70.7	<0.001		
Recurrent cholecystitis (%)	0	3.4	0.244		









Conclusions 结论

- EUS-guided biliary drainage increasing performed超声内镜引导下胆管引流越来越流行
 The procedure is opening new possibilities to access the biliary tract
 该程序打开进入胆道新的可能性
 Further large scale studies are required to assess how the procedure compares to traditional procedures
 进一步的大规模研究来评估程序的功效

